Third quarter 2026
Filed Nov 4, 2026Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Lumvoa generated first-quarter launch net product revenue of $24.7 million and more than 100 patients were on therapy, while research and development expense declined. However, total revenue declined against a prior-year period containing $70,000 in license revenue, selling, general and administrative expense increased to $57,609, and net loss widened to $101,209.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net, three months ended September 30, 2026 (in thousands)GAAP | $24.67M | – | – |
| License revenue, three months ended September 30, 2026 (in thousands)GAAP | 125K | – | – |
| Collaboration revenue - related parties, three months ended September 30, 2026 (in thousands)GAAP | 956K | – | – |
| Total revenues, three months ended September 30, 2026 (in thousands)GAAP | 25.75M | – | – |
| Cost of revenues, three months ended September 30, 2026 (in thousands)GAAP | 1.53M | – | – |
| Research and development, three months ended September 30, 2026 (in thousands)GAAP | 70.09M | – | – |
| Selling, general and administrative, three months ended September 30, 2026 (in thousands)GAAP | 57.61M | – | – |
| Total operating expenses, three months ended September 30, 2026 (in thousands)GAAP | 129.2M | – | – |
| Loss from operations, three months ended September 30, 2026 (in thousands)GAAP | −103.5M | – | – |
| Total other income, net, three months ended September 30, 2026 (in thousands)GAAP | 2.27M | – | – |
| Net loss, three months ended September 30, 2026 (in thousands)GAAP | −$101.2M | – | – |
| Net loss allocated to common stock, three months ended September 30, 2026 (in thousands)GAAP | −$91.44M | – | – |
| Net loss per share, basic and diluted, common stock, three months ended September 30, 2026GAAP | $ (0.81) | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 113,407,432 | – | – |
| Net loss allocated to Series A convertible preferred stock, three months ended September 30, 2026 (in thousands)GAAP | −$7.16M | – | – |
| Net loss per share, basic and diluted, Series A convertible preferred stock, three months ended September 30, 2026GAAP | $ (53.76) | – | – |
| Weighted-average Series A convertible preferred stock outstanding, basic and diluted, three months ended September 30, 2026GAAP | 133,191 | – | – |
| Net loss allocated to Series B convertible preferred stock, three months ended September 30, 2026 (in thousands)GAAP | −$2.60M | – | – |
| Net loss per share, basic and diluted, Series B convertible preferred stock, three months ended September 30, 2026GAAP | $ (53.76) | – | – |
| Weighted-average Series B convertible preferred stock outstanding, basic and diluted, three months ended September 30, 2026GAAP | 48,463 | – | – |
| Product revenue, net, nine months ended September 30, 2026 (in thousands)GAAP | $24.67M | – | – |
| License revenue, nine months ended September 30, 2026 (in thousands)GAAP | 364K | – | – |
| Collaboration revenue - related parties, nine months ended September 30, 2026 (in thousands)GAAP | 1.14M | – | – |
| Total revenues, nine months ended September 30, 2026 (in thousands)GAAP | 26.18M | – | – |
| Cost of revenues, nine months ended September 30, 2026 (in thousands)GAAP | 1.53M | – | – |
| Research and development, nine months ended September 30, 2026 (in thousands)GAAP | 219.3M | – | – |
| Selling, general and administrative, nine months ended September 30, 2026 (in thousands)GAAP | 151.3M | – | – |
| Total operating expenses, nine months ended September 30, 2026 (in thousands)GAAP | 372.1M | – | – |
| Loss from operations, nine months ended September 30, 2026 (in thousands)GAAP | −345.9M | – | – |
| Total other income, net, nine months ended September 30, 2026 (in thousands)GAAP | 12.69M | – | – |
| Net loss, nine months ended September 30, 2026 (in thousands)GAAP | −$333.2M | – | – |
| Net loss allocated to common stock, nine months ended September 30, 2026 (in thousands)GAAP | −$296.5M | – | – |
| Net loss per share, basic and diluted, common stock, nine months ended September 30, 2026GAAP | $ (2.75) | – | – |
| Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 107,875,408 | – | – |
| Net loss allocated to Series A convertible preferred stock, nine months ended September 30, 2026 (in thousands)GAAP | −$24.61M | – | – |
| Net loss per share, basic and diluted, Series A convertible preferred stock, nine months ended September 30, 2026GAAP | $ (183.26) | – | – |
| Weighted-average Series A convertible preferred stock outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 134,263 | – | – |
| Net loss allocated to Series B convertible preferred stock, nine months ended September 30, 2026 (in thousands)GAAP | −$12.10M | – | – |
| Net loss per share, basic and diluted, Series B convertible preferred stock, nine months ended September 30, 2026GAAP | $ (183.26) | – | – |
| Weighted-average Series B convertible preferred stock outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 66,004 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Lumvoa product revenue, net, three months ended September 30, 2026More than 100 patients were on therapy with Lumvoa as of September 30, 2026; the company cited significant market access progress and continued execution across field sales, medical, market access, and patient services. | $24.7M | – | – |
| License revenue, three months ended September 30, 2026 (in thousands)Not disclosed. | 125K | – | – |
| Collaboration revenue - related parties, three months ended September 30, 2026 (in thousands)Not disclosed. | 956K | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Q4 2026 and Q1 2027 outlook
- NoteViridian expects to submit a BLA to the U.S. FDA for elegrobart in TED in Q1 2027.
- NoteVRDN-292 IND on track to support phase 1 clinical trial initiation in Q4 2026, starting in patients with Graves’ disease.
- NoteViridian expects to announce VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio in Q4 2026.
- NoteExisting cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to be able to fund Viridian’s current business plans through profitability.
What drove it
- Lumvoa generated $24.7 million in net product revenue during its first quarter of launch.
- More than 100 patients were on therapy with Lumvoa at the end of Q3 2026.
- Research and development expense decreased due to reduced expenses related to veligrotug and elegrobart clinical studies, partially offset by additional investment in the TSHR program and FcRn portfolio and increased personnel-related costs.
- Selling, general and administrative expense increased due to personnel-related costs and professional services supporting Lumvoa commercial activities and the growing organization.
- CMS assigned Lumvoa permanent J-code J3242, effective January 1, 2027.
Concerns
- Net loss was $ (101,209) for the three months ended September 30, 2026, compared with $ (34,599) for the same period in 2025.
- Selling, general and administrative expense was 57,609 for the three months ended September 30, 2026, compared with 24,322 for the same period in 2025 (in thousands).
- Total revenues were 25,752 for the three months ended September 30, 2026, compared with 70,570 for the same period in 2025 (in thousands), when the company recorded 70,000 of license revenue.
- The planned elegrobart BLA submission, the VRDN-292 phase 1 initiation, and VRDN-008 data disclosure remain forward-looking milestones.
What to watch
- VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio expected in Q4 2026.
- VRDN-292 phase 1 clinical trial initiation in patients with Graves’ disease expected in Q4 2026.
- Elegrobart BLA submission for TED expected in Q1 2027.
- The January 1, 2027 effective date for Lumvoa permanent J-code J3242.
- Lumvoa patient adoption, market access progress, and net product revenue following the first quarter of launch.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities: $ 955,206 as of September 30, 2026, compared with $ 874,652 as of December 31, 2025 (in thousands).
- Accounts receivable, net: 29,782 as of September 30, 2026, compared with — as of December 31, 2025 (in thousands).
- Other assets: 43,682 as of September 30, 2026, compared with 24,766 as of December 31, 2025 (in thousands).
- Total assets: $ 1,028,670 as of September 30, 2026, compared with $ 899,418 as of December 31, 2025 (in thousands).
- Total liabilities: 447,972 as of September 30, 2026, compared with 177,251 as of December 31, 2025 (in thousands).
- Total stockholders’ equity: 580,698 as of September 30, 2026, compared with 722,167 as of December 31, 2025 (in thousands).
- Total liabilities and stockholders’ equity: $ 1,028,670 as of September 30, 2026, compared with $ 899,418 as of December 31, 2025 (in thousands).
- As of September 30, 2026, Viridian had 125,636,093 shares of common stock outstanding on an as-converted basis, including 113,525,222 shares of common stock and an aggregate 12,110,871 shares of common stock issuable upon conversion of 133,191 and 48,463 shares of Series A and Series B preferred stock, respectively.
Analysis
Viridian reported its first quarter of Lumvoa launch revenue, with net product revenue of $24.7 million and more than 100 patients on therapy as of September 30, 2026. Management highlighted market-access progress, continued commercial and medical execution, and the assignment of permanent J-code J3242 effective January 1, 2027. The company recorded no net product revenue in the comparable 2025 period.
Total revenues were 25,752 for the three months ended September 30, 2026, versus 70,570 in the prior-year period, in thousands. The year-ago period included 70,000 of license revenue, while current-quarter revenue was primarily product revenue. Collaboration revenue from related parties was 956 and license revenue was 125 in the current quarter, in thousands.
The expense mix reflects the commercial launch and ongoing pipeline investment. Research and development expense declined to 70,093 from 86,261, in thousands, driven by lower veligrotug and elegrobart clinical-study expenses, partly offset by TSHR and FcRn investment and higher personnel costs. Selling, general and administrative expense increased to 57,609 from 24,322, in thousands, due to personnel-related costs and professional services for Lumvoa commercial activities and organizational growth. Net loss widened to $ (101,209), compared with $ (34,599), in thousands.
Cash, cash equivalents, and marketable securities were $ 955,206 as of September 30, 2026, in thousands, compared with $ 874,652 as of December 31, 2025. Viridian stated that existing cash and anticipated commercial revenues from Lumvoa and elegrobart, if approved, are expected to fund current business plans through profitability. Near-term execution milestones are VRDN-008 phase 1 healthy-volunteer data and FcRn development plans, plus VRDN-292 phase 1 initiation, both expected in Q4 2026, followed by an elegrobart TED BLA submission expected in Q1 2027.
Management, verbatim
We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations.
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- Non-GAAP revenue, earnings, EPS, or expense measures were not reported.
- Prior-quarter financial comparisons were not reported.
- Operating cash flow and free cash flow were not reported.
- Debt was not reported.
- Share repurchases and dividends were not reported.
- A tax rate was not reported.
- Quantitative forward revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
- A previous outlook section was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.